In fact, PD-L2 expression has been shown to be predictive of longer progression free survival in patients with head and neck squamous cell carcinoma treated with pembrolizumab (anti-PD1) [28]. Here, PDCD1LG2 is linked to head and neck squamous cell carcinoma.